Research Article
Long-Term Effects of Ipragliflozin on Adipose Tissue in Japanese Patients with Obese Type 2 Diabetes
Nishio SI1,2*, Sekido T1, Ohkubo Y1,2, Takahashi T3, Oiwa A1, Kaneko A1 and Komatsu M11Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
2Research Center for Next Generation Medicine, Shinshu University School of Medicine, Matsumoto 390-8621, Japan
3Shinshu University Hospital, Department of Nursing, Matsumoto 390-8621, Japan
- Corresponding Author:
- Shin-ichi Nishio, M.D, Ph.D
Division of Diabetes, Endocrinology and Metabolism
Department of Internal Medicine, Shinshu University School of Medicine
3-1-1 Asahi, Matsumoto, 390-8621 Japan
Tel: +81-263-37-2686
E-mail: snishio@shinshu-u.ac.jp
Received Date: August 04, 2017; Accepted Date: August 11, 2017; Published Date: August 18, 2017
Citation: Nishio SI, Sekido T, Ohkubo Y, Takahashi T, Oiwa A, et al. (2017) Long-Term Effects of Ipragliflozin on Adipose Tissue in Japanese Patients with Obese Type 2 Diabetes. J Obes Weight Loss Ther 7:345. doi:10.4172/2165-7904.1000345
Copyright: © 2017 Nishio SI, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
A long-term effect of ipragliflozin on adipose tissue mass reduction by ipragliflozin in Japanese patients with obese type2 diabetes (mean BMI 35.1 ± 1.1 kg/m2) was investigated. 17 of 20 participants completed this study. Ipragliflozin was administered (50 mg/day) once daily for 12 months. At 0, 3, 6 and 12 months, visceral and subcutaneous adipose tissue area was determined by two different bioelectrical impedance methods, and blood samples for HbA1c, renal function, lipids and liver function obtained, and body weight and blood pressure recorded. The primary endpoint was decrease in body fat mass. Secondary endpoints included changes in body weight and the laboratory data. Visceral fat area (cm2, mean ± SD) at 0, 3, 6 and 12 months was 166.0 ± 49.7, 149.7 ± 46.1, 149.7 ± 42.4 and 148.5 ± 40.2, respectively: the value at 3 months was significantly lower than baseline (P=0.027). Subcutaneous fat at the corresponding time points was 359.3 ± 110.5, 316.6± 87.1, 326.8 ± 87.2 and 325.9 ± 90.4, respectively: the values at each post treatment period were significantly less than the baseline (P=0.003, 0.018 and 0.036 for the three points, respectively). Body weight was significantly reduced by 12 months (P=0.045). Serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transpeptidase levels decreased significantly. There was no significant correlation between serum hepatobiliary enzyme levels and γ-body weight or visceral fat. But γ-GTP was correlated with subcutaneous fat (Spearman’s P=0.004). During 1 year-interval, ipragliflozin significantly reduced subcutaneous adipose tissue and serum hepatobiliary enzyme levels, and may be useful in patients with obese diabetes.